Depressive Disorder and Anxiety Disorders Clinical Trial
Official title:
Placebo-Controlled, Randomized, Blinded, Double-Dummy, Crossover Study to Investigate the Attenuation of ACTH Activation Induced by Metyrapone With a Single Dose of GSK561679 or Alprazolam in Healthy Volunteers
A study to investigate the effects GSK561679 on part of the body's system that controls the balance of many of the hormones (including cortisol).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00536679 -
Relative Bioavailability and Food Effect Study for GSK163090 in Healthy Male and Female Volunteers
|
Phase 1 | |
| Completed |
NCT01424384 -
Emotional Processing in Healthy Volunteers in the Presence of an Investigational Anxiolytic
|
Phase 1 | |
| Completed |
NCT00513565 -
A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01031186 -
First Time in Human Study
|
Phase 1 | |
| Completed |
NCT00435695 -
Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using PET Imaging In Healthy Males
|
Phase 1 | |
| Completed |
NCT00343707 -
PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of 2 Medications In Social Anxiety Patients
|
Phase 2 | |
| Completed |
NCT01059591 -
First Study in Humans With GSK424887
|
Phase 1 | |
| Completed |
NCT01059578 -
First Study in Humans With GSK206136
|
Phase 1 | |
| Completed |
NCT00703547 -
A First Time in Human Study of GSK586529 in Healthy Volunteers
|
Phase 1 |